StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > HOPING THIS IS A LEAK

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Feb 24, 2021 2:26pm

67 Views

Post# 32648921

RE:RE:HOPING THIS IS A LEAK

If they did in fact hire an additional 12 according to the prospectus plan that puts them at 47 employees. I would think that they would be able to run with 2 revenue streams until covid drops off. They were also looking at expanding the lab and some of the posts showed weekend or shift work. So should be able to run both

The perfect scenario.

But hey just guessing since no updates.

Saaweeeetdreams wrote: The only way Aristotle gets held back is Covid test take up all the capacity at the lab to preform any other tests!! That would be a good negative?!

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023